The modified surface killing assay distinguishes between protective and nonprotective antibodies to PspA

Genschmer, Kristopher R.; Vadesilho, Cintia Fiuza Marques; McDaniel, Larry S.; Park, Sang-Sang; Hale, Yvette; Miyaji, Eliane Namie; Briles, David E..
mSphere, v. 4, n. 6, p. e00589-19, dec. 2019
Artículo en Inglés | SES-SP, SESSP-IBPROD, SES-SP | ID: bud-2880

Documentos relacionados

  1. The modified surface killing assay distinguishes between protective and nonprotective antibodies to PspA
  2. The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA.
  3. In-silico design and evaluation of an epitope-based serotype-independent promising vaccine candidate for highly cross-reactive regions of pneumococcal surface protein A.
  4. High-Throughput and Format-Agnostic Mispairing Assay for Multispecific Antibodies Using Intact Mass Spectrometry.
  5. Synergistic Protection against Secondary Pneumococcal Infection by Human Monoclonal Antibodies Targeting Distinct Epitopes.
  6. The dual action of human antibodies specific to Plasmodium falciparum PfRH5 and PfCyRPA: Blocking invasion and inactivating extracellular merozoites.
  7. A Powassan virus domain III nanoparticle immunogen elicits neutralizing and protective antibodies in mice.
  8. Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein.
  9. Cross-reaction mediated by distinct key amino acid combinations in the complementary-determining region (CDR) of a monoclonal antibody.
  10. The CDE region of feline Calicivirus VP1 protein is a potential candidate subunit vaccine.